StockWatch: Athira Pays Price as Alzheimer's Candidate Fails Trial
Kort samengevat
Athira Pharma (ATHA) saw its shares tailspin 81% after its lead candidate fosgonimeton failed the Phase II/III LIFT-AD clinical trial.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij GEN - Genetic Engineering and Biotechnology News.
Lees het volledige bericht ↗